Psoriasin expression by breast epithelial cells
AssigneeDana-Farber Cancer Institute, Inc.
InventorsKornelia Polyak, Charlotta Enerbäck
Life of this patent
Estimating the term…
Abstract
The invention features methods of diagnosing high grade ductal carcinoma in situ (DCIS) These methods involve measuring: (1) the level of HID-5 in a body fluid (e.g., blood or urine) of a subject suspected of having, or at risk of having, high grade DCIS; or (2) the level of HID-5 gene expression in breast tissue from a subject suspected of having, or at risk of having, high grade DCIS. The invention also embodies a method of inhibiting expression of HID-5 protein in DCIS cells and methods of treating a subject suspected of having, or at risk of having, high grade DCIS.
Claims5
A method of diagnosis, the method comprising:
- (a) identifying a subject suspected of having or at risk of having high-grade ductal carcinoma in situ (DCIS);
- and
- (b) measuring the level of psoriasin in a sample of a body fluid, a lavage, or an aspirate from the subject,
- wherein an elevated level of psoriasin in the sample, compared to a control level of psoriasin, is an indication that the subject has high grade DCIS.
Dependencies are inferred from the claim text.